Congratulations to the entire Northside Cancer Institute Blood Cancer and Hematologic Malignancy Programs. All four Northside hospitals received a High Performing designation for the treatment of multiple myeloma, leukemia, and non-Hodgkin lymphoma.

This achievement reflects the depth and breadth of our program, which brings together clinical expertise, research, transplant capabilities, cellular therapies, and multidisciplinary care to provide comprehensive and innovative treatment for patients facing complex hematologic malignancies.

Our program offers:

• High-volume care for leukemia, multiple myeloma, and non-Hodgkin lymphoma

• An academically based clinical research portfolio

• Outpatient autologous and allogeneic bone marrow transplantation

• Haploidentical and alternative-donor transplantation

• FDA-approved commercial and clinical-trial CAR-T therapies

• Novel immune effector cell (IEC) therapies

• Specialized GVHD management

• Dedicated inpatient and outpatient infrastructure

This recognition is a reflection of the people at the heart of our program—our patients and their families, as well as the dedicated physicians, nurses, researchers, advanced practice providers, pharmacists, therapists, and support teams who make exceptional care possible every day.

We are honored by this recognition and grateful to the entire Northside Blood Cancer Program for itscommitment to advancing cancer care and improving outcomes for our patients.